Claimed effect · Orforglipron

Does Orforglipron help with major cardiovascular events?

B
Grade B — probable, not settled1 phase 3 safety RCT (ACHIEVE-4, n=2,749, median 2 yr) · effect size: not measurable
Short answerProbable, not settled. Human data exist (1 phase 3 safety RCT (ACHIEVE-4, n=2,749, median 2 yr)) and mostly agree, showing no measurable effect, or none yet shown — but too few, too small, or not yet peer-reviewed for a firm answer. ACHIEVE-4, published in The Lancet on 30 September 2026: adults with type 2 diabetes, overweight or obesity and established cardiovascular or chronic kidney disease took orforglipron or insulin glargine, open label. A major cardiovascular event occurred in 4.2% on orforglipron and 5.0% on glargine (hazard ratio 0.84, 95% CI 0.59–1.20). That meets non-inferiority, so cardiovascular safety is confirmed; the interval crosses 1, so a reduction in events is not shown. Deaths were 1.4% against 3.2%, in a trial built to test safety, not that difference. Clinically significant hypoglycaemia: 6.8% vs 19.2%.

What the studies show

ACHIEVE-4, published in The Lancet on 30 September 2026: adults with type 2 diabetes, overweight or obesity and established cardiovascular or chronic kidney disease took orforglipron or insulin glargine, open label. A major cardiovascular event occurred in 4.2% on orforglipron and 5.0% on glargine (hazard ratio 0.84, 95% CI 0.59–1.20). That meets non-inferiority, so cardiovascular safety is confirmed; the interval crosses 1, so a reduction in events is not shown. Deaths were 1.4% against 3.2%, in a trial built to test safety, not that difference. Clinically significant hypoglycaemia: 6.8% vs 19.2%.

“Over a median follow-up of 2 years, the primary outcome occurred in 57 (4·2%) of 1358 orforglipron participants and 67 (5·0%) of 1343 insulin glargine participants, showing non-inferiority to insulin glargine for MACE-4 (HR 0·84; 95% CI 0·59-1·20; p<0·0001 for non-inferiority).”

Verbatim, from the abstractKlein KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet, 2026 (online 30 Sep)

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Klein KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.Lancet, 2026 (online 30 Sep)2,749 randomised, 317 sites, median follow-up 2 years; MACE-4 hazard ratio 0.84 (95% CI 0.59–1.20), non-inferiority margin 1.8. NCT05803421.

In context

Orforglipron (Foundayo) is a once-daily tablet that activates the GLP-1 receptor. It is not a peptide — it is a small molecule, which is why it survives digestion and needs no injection, refrigeration or food restriction. Its phase 3 programme is published: about 11% average weight loss over 72 weeks in obesity, and HbA1c reductions of roughly 1.5 points in early type 2 diabetes. The FDA approved it for weight management on 1 April 2026. The effect is smaller than injected tirzepatide or semaglutide; the delivery is far easier.

Orforglipron is approved (rx) — united states. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Orforglipron proven to help with major cardiovascular events?
Not yet settled. 1 phase 3 safety RCT (ACHIEVE-4, n=2,749, median 2 yr) — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
ACHIEVE-4, published in The Lancet on 30 September 2026: adults with type 2 diabetes, overweight or obesity and established cardiovascular or chronic kidney disease took orforglipron or insulin glargine, open label. A major cardiovascular event occurred in 4.2% on orforglipron and 5.0% on glargine (hazard ratio 0.84, 95% CI 0.59–1.20). That meets non-inferiority, so cardiovascular safety is confirmed; the interval crosses 1, so a reduction in events is not shown. Deaths were 1.4% against 3.2%, in a trial built to test safety, not that difference. Clinically significant hypoglycaemia: 6.8% vs 19.2%.
Is Orforglipron approved for this?
Orforglipron is an approved medicine (Approved (Rx) — United States); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Orforglipron

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →